Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required

Ir J Med Sci. 2023 Feb;192(1):19-25. doi: 10.1007/s11845-022-02984-1. Epub 2022 Mar 28.

Abstract

Aims: Despite high vaccination rates, increasing case numbers continue to be reported with the identification of new variants of concern, and the issue of durability of the vaccine-induced immune response remains hot topic. Real-life data regarding time-dependent immunogenicity of inactivated COVID-19 vaccines are scarce. We aimed to investigate the changes in the antibody at the different times after the second dose of the CoronaVac vaccine.

Methods: The study included 175 HCWs vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses. Anti-spike/RBD IgG levels were measured first, third, and sixth months after the second dose. Chemiluminescent microparticle immunoassay (IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test, was used.

Results: Mean age of the participants was 38 ± 11.23 years (range between 22 and 66) of whom 119 (63.9%) were female, and 56 (32%) were male. Dramatic reductions were demonstrated in median antibody levels particularly in the infection-naïve group, comprising 138 HCWs compared to those with prior history of COVID-19 infection (n = 37) (p < 0.001). There was no difference between the two groups in terms of age, gender, blood groups, BMI, and comorbid diseases.

Conclusions: While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly. The decrease was more rapid and significant in those with no history of prior COVID-19 infection. In this critical phase of the pandemic, where we are facing the dominance of the Omicron variant after Delta, booster doses have become vital.

Keywords: COVID-19; Inactive vaccine; Neutralizing antibody; Sinovac.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Female
  • Health Personnel
  • Humans
  • Immunoglobulin G
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Young Adult

Substances

  • sinovac COVID-19 vaccine
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants